Mersana Therapeutics, Inc. Analyst EPS Estimates
| Quarter | Number of Estimates | Low Estimate | High Estimate | Average Estimate |
|---|---|---|---|---|
| Q1 2024 | 2 | -$0.18 | -$0.18 | -$0.18 |
| Q2 2024 | 2 | -$0.17 | -$0.17 | -$0.17 |
| Q3 2024 | 7 | -$0.22 | -$0.14 | -$0.17 |
| Q4 2024 | 2 | -$0.17 | -$0.17 | -$0.17 |
| Q1 2025 | 3 | -$0.21 | -$0.21 | -$0.21 |
| Q2 2025 | 3 | -$0.21 | -$0.21 | -$0.21 |
| Q3 2025 | 6 | -$0.21 | -$0.21 | -$0.21 |
| Q4 2025 | 5 | -$0.19 | -$0.19 | -$0.19 |
| Q1 2026 | 4 | -$0.17 | -$0.17 | -$0.17 |
| Q2 2026 | 3 | -$0.14 | -$0.14 | -$0.14 |
| Q3 2026 | 2 | -$0.14 | -$0.14 | -$0.14 |
| Q4 2026 | 2 | -$0.14 | -$0.14 | -$0.14 |
Mersana Therapeutics, Inc. Earnings Date And Information
Mersana Therapeutics, Inc. last posted its earnings results on Tuesday, August 13th, 2024. The company reported $-0.2 earnings per share for the quarter, missing analysts' consensus estimates of $-0.18 by $0.02. The company had revenue of 2.29 M for the quarter and had revenue of 36.86 M for the year. Mersana Therapeutics, Inc. has generated $-1 earnings per share over the last year ($-1.48 diluted earnings per share) and currently has a price-to-earnings ratio of -2.33. Mersana Therapeutics, Inc. has not formally confirmed its next earnings publication date, but the company's estimated earnings date is Tuesday, November 5th, 2024 based on prior year's report dates.
Mersana Therapeutics, Inc. Earnings History by Quarter
| Date | Quarter | Consensus Estimate | Reported EPS | Beat/Miss | Revenue Estimate | Actual Revenue |
|---|---|---|---|---|---|---|
| 08/13/2024 | Q2 2024 | -$0.18 | -$0.20 | -0.02 | $8.72 M | $2.29 M |
| 05/09/2024 | Q1 2024 | -$0.18 | -$0.16 | 0.02 | $9.25 M | |
| 02/28/2024 | Q4 2023 | -$0.20 | -$0.16 | 0.04 | $10.70 M | |
| 11/07/2023 | Q3 2023 | -$0.31 | -$0.35 | -0.04 | $9.60 M | $7.70 M |
| 08/08/2023 | Q2 2023 | -$0.39 | -$0.47 | -0.08 | $12.93 M | $10.65 M |
| 05/09/2023 | Q1 2023 | -$0.41 | -$0.53 | -0.12 | $7.80 M | |
| 02/28/2023 | Q4 2022 | -$0.47 | -$0.45 | 0.02 | $14.69 M | |
| 11/07/2022 | Q3 2022 | -$0.09 | -$0.61 | -0.52 | $56.78 M | $5.57 M |
| 08/08/2022 | Q2 2022 | -$0.50 | -$0.55 | -0.05 | $2.20 M | $4.28 M |
| 05/09/2022 | Q1 2022 | -$0.31 | -$0.60 | -0.29 | $2.04 M | |
| 02/28/2022 | Q4 2021 | -$0.67 | -$0.68 | -0.01 | $11,000 | |
| 11/09/2021 | Q3 2021 | -$0.58 | -$0.63 | -0.05 | $120,500 | $11,000 |
| 08/06/2021 | Q2 2021 | -$0.50 | -$0.59 | -0.09 | $170,000 | $11,000 |
| 05/10/2021 | Q1 2021 | -$0.39 | -$0.50 | -0.11 | $11,000 | |
| 02/26/2021 | Q4 2020 | -$0.33 | -$0.42 | -0.09 | $11,000 | |
| 11/09/2020 | Q3 2020 | -$0.31 | -$0.33 | -0.02 | $439,200 | $11,000 |
| 08/07/2020 | Q2 2020 | -$0.30 | -$0.33 | -0.03 | $306,000 | $796,000 |
| 05/08/2020 | Q1 2020 | -$0.38 | -$0.35 | 0.03 | $11,000 | |
| 02/28/2020 | Q4 2019 | -$0.38 | -$0.34 | 0.04 | $42,000 | |
| 11/06/2019 | Q3 2019 | -$0.37 | -$0.35 | 0.02 | $350,000 | $844,000 |
Mersana Therapeutics, Inc. Earnings: Frequently Asked Questions
-
When is Mersana Therapeutics, Inc.'s earnings date?
Mersana Therapeutics, Inc. has not confirmed its next earnings publication date, but the company's estimated earnings date is Tuesday, November 5th, 2024 based off last year's report dates.
-
How can I listen to Mersana Therapeutics, Inc.'s earnings conference call?
The conference call for Mersana Therapeutics, Inc.'s latest earnings report can be listened to online.
-
How can I read Mersana Therapeutics, Inc.'s conference call transcript?
The conference call transcript for Mersana Therapeutics, Inc.'s latest earnings report can be read online.
-
How much revenue does Mersana Therapeutics, Inc. generate each year?
Mersana Therapeutics, Inc. (:MRSN) has a recorded annual revenue of $36.86 M.
-
How much profit does Mersana Therapeutics, Inc. generate each year?
Mersana Therapeutics, Inc. (:MRSN) has a recorded net income of $36.86 M. Mersana Therapeutics, Inc. has generated $-1.48 earnings per share over the last four quarters.
-
What is Mersana Therapeutics, Inc.'s price-to-earnings ratio?
Mersana Therapeutics, Inc. (:MRSN) has a price-to-earnings ratio of -2.33 and price/earnings-to-growth ratio is -0.1.
